Long-term follow-up for young women after a heart attack
Official title: WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction in France: Clinical, Morphological and Biological Descriptive Analysis: Cohort Follow up
Run by French Cardiology Society · NCT07181317 · Data updated 2026-11-12
This follow-up will see if tracking health outcomes, quality of life, and mental health over time helps understand risks for women who had a heart attack before age 50.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | Women only |
| Enrollment | 314 (estimated) |
| Sponsor | French Cardiology Society Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | November 25, 2025 |
| Main results expected | September 30, 2029 |
| Study ends | September 30, 2029 |
| Registry record updated | January 12, 2026 |
| Trial ID | NCT07181317 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women who originally participated in the WAMIF cohort (registration 2015-A01263-46 / NCT03073447), had an MI before age 50, and consent to continued follow-up are eligible.
✕Probably not a fit
People who did not take part in the original WAMIF cohort or those with life-limiting non-cardiac conditions are unlikely to gain benefit from this extended cardiac follow-up.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The original WAMIF cohort enrolled 314 women under age 50 with acute myocardial infarction across 30 French centers from 2017–2019 and collected clinical, morphological, and biological data through 12 months. This extension continues observational follow-up beyond 12 months and captures major cardiovascular events along with standardized patient questionnaires on quality of life and mental health. No new treatments are given; data collection relies on medical records, event reporting, and patient-reported outcome measures. The extended data set will characterize long-term outcomes, recurrent events, and persistent modifiable risk factors in this young female MI population.
Why it matters
Potential benefit: If successful, the findings could help clinicians tailor long-term follow-up and prevention for women who have an MI at a young age.
How similar studies have gone: Other observational cohort follow-ups in young MI populations have provided useful long-term outcome and risk-factor data, but extended follow-up in this specific French WAMIF cohort is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
All patients who participated in the WAMIF study (research registration number with the French Ministry of Health : 2015-A01263-46 / Protocol registration with Clinical Trials NCT03073447) and wish to continue follow-up in the study.
Where it's running
-
Hôpital de la Pitié Salpétrière
Paris, France Recruiting
Study contacts
- Principal investigator: Stéphane MANZO SILBERMAN, MD — Hôpital de la Pitié-Salpêtrière, APHP
- Study coordinator: Tessa BERGOT, MSc
- Email: tessa.bergot@sfcardio.fr
- Phone: +33144907033
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rapid high-sensitivity Troponin I testing in ambulance care
This tests whether a rapid high-sensitivity troponin I blood test used by ambulance crews helps identify heart attacks earlier in people with chest pain or suspected myocardial infarction.
-
Understanding genetic factors in young adults with heart attacks
This study is trying to find out how genetics might play a role in heart attacks for young adults under 60 who don’t have typical heart disease risk factors.
-
Registry for tracking acute heart attacks
This study is tracking heart attacks in Tomsk, Russia, to see how many people are affected and how they are doing over time.
-
Effect of intravenous iron treatment on heart health and quality of life in patients with recent heart attacks and iron deficiency
This study is testing if giving intravenous iron to people with recent heart attacks and low iron levels can improve their heart health and quality of life.
-
Using eplerenone to treat heart injury in patients with small vessel disease
This study is testing if the medication eplerenone can help reduce heart damage and improve recovery for patients with heart injuries caused by small vessel disease.
-
Evaluating revascularization strategies for patients with NSTEMI and multivessel coronary artery disease
This study is testing whether treating all blocked heart arteries right away or doing it in stages is better for people with NSTEMI and multiple blocked arteries.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.